Bank of New York Mellon Corp Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bank of New York Mellon Corp grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 698,253 shares of the biopharmaceutical company's stock after acquiring an additional 8,990 shares during the quarter. Bank of New York Mellon Corp owned about 0.64% of Regeneron Pharmaceuticals worth $442,853,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. Finally, Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $32,000. Institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the topic of a number of research analyst reports. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective on the stock. Bank of America cut their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. Finally, Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $822.58.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $9.25 during trading on Monday, reaching $538.11. The company's stock had a trading volume of 959,668 shares, compared to its average volume of 907,598. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The company's fifty day moving average is $549.38 and its 200-day moving average is $624.74. The company has a market capitalization of $58.09 billion, a P/E ratio of 13.70, a price-to-earnings-growth ratio of 2.00 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the prior year, the business posted $9.55 EPS. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.